Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2− advanced breast cancer treated with CDK4/6 inhibitors
We showed in a large real-world series that most patients with HR+/HER2- ABC failing CDK4/6i and ET unselected for the occurrence of molecular mutations retain endocrine sensitivity and may benefit of a subsequent ET ± a targeted therapy delaying the need for chemotherapy regardless of site of progression and prior CDK4/6i therapy duration.
Authors
- De Sanctis R
- Rosalba Torrisi (ORCID: https://orcid.org/0000-0001-8344-6849)
- Ambra Carnevale Schianca
- Nadia Bianco (ORCID: https://orcid.org/0000-0001-5765-7765)
- Giuseppe Saltalamacchia (ORCID: https://orcid.org/0000-0002-0247-3835)
- Claudia Sangalli
- Flavia Jacobs
- Laura Giordano
- Giovanna Masci
- Monica Milano
- Armando Santoro
- Giuseppe Curigliano
- Federica Giugliano
Institutions
- Humanitas University (IT)
- University of Milan (IT)
- IRCCS Humanitas Research Hospital (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1093/oncolo/oyag003
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00